Free Trial
ASX:SOM

SomnoMed (SOM) Stock Price, News & Analysis

About SomnoMed Stock (ASX:SOM)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
95,124 shs
Average Volume
N/A
Market Capitalization
$136.15 million
P/E Ratio
N/A
Dividend Yield
2.25%
Price Target
N/A
Consensus Rating
N/A

Company Overview

SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral appliances for the treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. Its flagship product SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs are cleaning tablets, developed to clean oral appliances safely and effectively. In addition, it also provides sleep test at home under the Sunrise brand name. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.

Receive SOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SomnoMed and its competitors with MarketBeat's FREE daily newsletter.

SOM Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
SomnoMed Limited Announces AGM Resolutions Approval
SomnoMed Projects Growth and Appoints New CFO
SomnoMed Limited Sees Growth and Innovation in 2024
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
ASX:SOM
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
-0.09
Net Income
$-12,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$91.65 million
Price / Cash Flow
7.61
Book Value
A$0.37 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$136.15 million
Optionable
Not Optionable
Beta
1.37
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (ASX:SOM) was last updated on 5/13/2025 by MarketBeat.com Staff
From Our Partners